Search Results - Jueliger, Simone

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma

    Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma by Ferrari, Nicola, Ward, George, Gewinner, Christina, Davis, Matthew P., Jueliger, Simone, Saini, Harpreet, Munck, Joanne, Smyth, Tomoko, Ferraldeschi, Roberta, Keer, Harold, Lyons, John, Sims, Martin J.

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma

    Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma by Jueliger, Simone, Lyons, John, Cannito, Sara, Pata, Illar, Pata, Pille, Shkolnaya, Marianna, Lo Re, Oriana, Peyrou, Marion, Villarroya, Francesc, Pazienza, Valerio, Rappa, Francesca, Cappello, Francesco, Azab, Mohammad, Taverna, Pietro, Vinciguerra, Manlio

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses

    A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses by Matei, Daniela, Ghamande, Sharad, Roman, Lynda, Secord, Angeles Alvarez, Nemunaitis, John, Markham, Merry Jennifer, Nephew, Kenneth P., Jueliger, Simone, Oganesian, Aram, Naim, Sue, Su, Xiang Yao, Keer, Harold, Azab, Mohammad, Fleming, Gini F

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing

    Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing by Riccadonna, Cristina, Yacoub Maroun, Céline, Vuillefroy de Silly, Romain, Boehler, Margaux, Calvo Tardón, Marta, Jueliger, Simone, Taverna, Pietro, Barba, Leticia, Marinari, Eliana, Pellegatta, Serena, Bassoy, Esen Yonca, Martinvalet, Denis, Dietrich, Pierre-Yves, Walker, Paul R.

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    First-in-human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors

    First-in-human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors by McLeod, Robert, Kumar, Rajiv, Papadatos-Pastos, Dionysis, Mateo, Joaquin, Brown, Jessica S, Garces, Alvaro H Ingles, Ruddle, Ruth, Decordova, Shaun, Jueliger, Simone, Ferraldeschi, Roberta, Maiques, Oscar, Sanz-Moreno, Victoria, Jones, Paul, Traub, Stephanie, Halbert, Gavin, Mellor, Sarah, Swales, Karen E, Raynaud, Florence I, Garrett, Michelle D, Banerji, Udai

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

    A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure by Sébert, Marie, Renneville, Aline, Bally, Cécile, Peterlin, Pierre, Beyne-Rauzy, Odile, Legros, Laurence, Gourin, Marie-Pierre, Sanhes, Laurence, Wattel, Eric, Gyan, Emmanuel, Park, Sophie, Stamatoullas, Aspasia, Banos, Anne, Laribi, Kamel, Jueliger, Simone, Bevan, Luke, Chermat, Fatiha, Sapena, Rosa, Nibourel, Olivier, Chaffaut, Cendrine, Chevret, Sylvie, Preudhomme, Claude, Adès, Lionel, Fenaux, Pierre

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer

    A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer by Oza, Amit, Matulonis, Ursula, Alvarez Secord, Angeles, Roman, Lynda, Blagden, Sarah, Banerjee, Susana, Nemunaitis, John, McGuire, William, Ghamande, Sharad, Birrer, Michael, Fleming, Gini F, Jennifer Markham, Merry, Hirte, Hal, Provencher, Diane, Basu, Bristi, Kristeleit, Rebecca, Armstrong, Deborah, Schwartz, Benjamin, Braly, Patricia, Hall, Geoffrey, Nephew, Kenneth P., Jueliger, Simone, Oganesian, Aram, Naim, Sue, Hao, Yong, Keer, Harold, Azab, Mohammad, Matei, Daniela

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: